Nektar Therapeutics (NASDAQ: NKTR) shares vaulted 12.1% on June 24 to close at $9.54, reversing a four-week slump of 13.2%. The surge came on heavy volume as investors cheered top-line data from the Phase IIb REZOLVE-AD study of rezpegaldesleukin—Nektar’s lead candidate for moderate-to-severe atopic dermatitis.
Today’s price snapshot
- Closing price: $9.54 (up 12.1%)
- Four-week return: –13.2%
- Average daily volume: more than double usual
Clinical catalyst: REZOLVE-AD data
The rally was driven by optimism over midstage results showing:
- EASI improvement: 53–61% symptom reduction vs. 31% for placebo
- Dose response: Statistically significant itch relief at middle and high doses
- Safety profile: No increased risk of conjunctivitis or herpes outbreaks
CEO Howard Robin said the data “establish a new biology” for regulatory T-cell therapies, positioning rezpegaldesleukin for further development in inflammatory and autoimmune conditions.
Earnings outlook and estimate revisions
Nektar is expected to report a quarterly loss of $2.53 per share (-32.5% YoY) and revenue of $10.78 million (-54.1% YoY). However, analysts have raised their EPS forecasts, with the consensus estimate up 10.5% over the last 30 days—a strong bullish signal that often presages further price gains.
Zacks Rank and industry peers
- Zacks Rank: #3 (Hold)
- Industry: Medical – Drugs
- Peer comparison: Indivior PLC (INDV) trades at $13.95 (-0.4% on June 24), with flat EPS estimates and a #3 rank. INDV has returned +24.4% over the past month, underscoring the volatility in drug-development plays.
What to watch next
- Upcoming earnings report: Confirmation of guidance trends will be critical.
- Volume trends: Continued heavy trading would support sustained momentum.
- Further trial updates: Expansion into alopecia areata and other indications could be additional catalysts.
- Regulatory milestones: Any Fast Track or Breakthrough Therapy designations would boost visibility.
MORE FROM FINGERLAKES1.COM
This content is brought to you by the FingerLakes1.com Team. Support our mission by visiting www.patreon.com/fl1 or learn how you send us your local content here.
